- Home
- AIRT vs ATNM Comparison
AIRT vs ATNM Comparison
Compare AIRT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ATNM
- Stock Information
- Founded
- AIRT 1980
- ATNM 2000
- Country
- AIRT United States
- ATNM United States
- Employees
- AIRT N/A
- ATNM N/A
- Industry
- AIRT Air Freight/Delivery Services
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- ATNM Health Care
- Exchange
- AIRT Nasdaq
- ATNM Nasdaq
- Market Cap
- AIRT 53.2M
- ATNM 51.5M
- IPO Year
- AIRT N/A
- ATNM N/A
- Fundamental
- Price
- AIRT $21.13
- ATNM $1.43
- Analyst Decision
- AIRT
- ATNM Strong Buy
- Analyst Count
- AIRT 0
- ATNM 3
- Target Price
- AIRT N/A
- ATNM $4.67
- AVG Volume (30 Days)
- AIRT 2.7K
- ATNM 514.9K
- Earning Date
- AIRT 06-27-2025
- ATNM 08-04-2025
- Dividend Yield
- AIRT N/A
- ATNM N/A
- EPS Growth
- AIRT N/A
- ATNM N/A
- EPS
- AIRT N/A
- ATNM N/A
- Revenue
- AIRT $291,850,000.00
- ATNM N/A
- Revenue This Year
- AIRT N/A
- ATNM N/A
- Revenue Next Year
- AIRT N/A
- ATNM N/A
- P/E Ratio
- AIRT N/A
- ATNM N/A
- Revenue Growth
- AIRT 1.75
- ATNM N/A
- 52 Week Low
- AIRT $14.56
- ATNM $1.03
- 52 Week High
- AIRT $30.60
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- AIRT 54.46
- ATNM 44.02
- Support Level
- AIRT $18.86
- ATNM $1.41
- Resistance Level
- AIRT $22.50
- ATNM $1.95
- Average True Range (ATR)
- AIRT 1.12
- ATNM 0.12
- MACD
- AIRT -0.05
- ATNM -0.03
- Stochastic Oscillator
- AIRT 47.07
- ATNM 22.22
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.